Search
lorlatinib (Lorbrena)
Indications:
- treatment of ALK-positive non-small cell lung cancer [2,3]
Dosage:
Tabs: 25 mg, 100 mg
Pharmacokinetics:
- crosses blood brain barrier
Mechanism of action:
- binds to & inhibits both anaplastic lymphoma kinase (ALK) & ROS1 kinase
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=71731823
References
- PubChem: 71731823
- Otto MA
Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?
Medscape - Sep 23, 2020.
https://www.medscape.com/viewarticle/937935
- Shaw AT, Bauer TM, de Marinis F et al
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med 2020; 383:2018-2029
PMID: 33207094
https://www.nejm.org/doi/full/10.1056/NEJMoa2027187